



## **Tactile Medical to Ring the Nasdaq Stock Market Opening Bell**

January 17, 2017

MINNEAPOLIS, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Tactile Systems Technology Inc. ("Tactile Medical") (Nasdaq:TCMD), a leader in developing and marketing at-home therapy devices that treat lymphedema and venous ulcers, will celebrate its 2016 initial public offering ("IPO") by ringing the Nasdaq Stock Market opening bell in New York City on Tuesday, January 17. The Company began trading on the Nasdaq Global Market on July 28, 2016.

"Tactile Medical is honored to ring the opening bell as it marks a celebration of the successful pricing of our IPO during the third quarter, as well as the efforts of our employees and our investors that have brought the company to this stage," shared Gerald Mattys, Chief Executive Officer. "This event also represents an exciting start to what we believe will be another promising year for the company."

Mattys will be joined by several members of the Tactile Medical management team as he rings the opening bell at 9:30 a.m. ET. Coverage begins at 9:20 a.m. ET. A live feed of the event can be found at <https://livestream.com/nasdaq/live>.

To learn more about Tactile Medical please visit [TactileMedical.com](http://TactileMedical.com).

### **About Tactile Medical:**

Tactile Systems Technology, Inc. ("Tactile Medical") is a medical technology company that develops and provides innovative medical devices for the treatment of chronic diseases at home. The Company is the sole manufacturer and distributor of the Flexitouch and Entré™ Systems, medical devices to help control symptoms of lymphedema, a chronic and progressive medical condition that is often an unintended consequence of cancer treatment, and the ACTitouch® System, a medical device to treat venous leg ulcers and chronic venous insufficiency. The Company provides products for use both in the home and in health care institutions, including hospitals and vascular, wound and lymphedema clinics throughout the United States. For additional information, please visit <http://www.tactilemedical.com>. To receive future press releases via email, please visit [Investors.tactilemedical.com](mailto:Investors.tactilemedical.com).

### **Legal Notice Regarding Forward-Looking Statements:**

This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the Company's control that can make such statements untrue, including, but not limited to, the adequacy of the Company's liquidity to pursue its complete business objectives; the Company's ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of a key supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company's products; technical problems with the Company's research and products; the Company's ability to expand its business through strategic acquisitions; the Company's ability to integrate acquisitions and related businesses; price increases for supplies and components; and the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in the Company's filings with the SEC, including the final prospectus for the Company's initial public offering. Investors and security holders are urged to read these documents free of charge on the SEC's web site at <http://www.sec.gov>. The Company undertakes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

### **Investor Inquiries:**

Mike Piccinino, CFA  
Managing Director  
Westwicke Partners  
433-213-0500  
[investorrelations@tactilemedical.com](mailto:investorrelations@tactilemedical.com)

### **Media Inquiries:**

Kristen Weaver  
Director of Marketing Communications  
Tactile Medical  
612-355-5156  
[kweaver@tactilemedical.com](mailto:kweaver@tactilemedical.com)

 Primary Logo

Tactile Systems Technology